$NAMS Cashflow Statement | Understand Stock

$NAMS

$20.55 +$0.05 (0.24%) Live

$NAMS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022
Operating Activities:
Loss for the year
Depreciation and amortization
Share listing expense
Finance income
Finance expense
Fair value change - derivative earnout and warrants
Foreign exchange gains/(losses)
Share-based compensation
Changes in prepayments and other receivables
Changes in trade and other payables
Changes in deferred revenue
Interest paid
Net cash provided by/(used in) operating activities
Purchase of equipment
Repayment of loan receivable
Net cash provided by/(used in) investing activities
Transaction costs on issue of shares
Repayment
Net cash provided by financing activities
Net increase in cash
Foreign exchange differences
Cash at the beginning of the year
Cash at the end of the year
Non-cash adjustments to reconcile loss for the year to net cash flows:
Depreciation and amortization
Non-cash rent expense
Fair value change - tranche rights
Fair value change - IPR&D
Fair value change - derivative earnout and warrants
Loss on disposal of property, plant and equipment
Foreign exchange (gains)/losses
Amortization of premium/discount on available-for-sale debt securities
Share-based compensation
Changes in working capital:
Changes in prepayments (current and non-current) and other receivables
Changes in accounts payable
Changes in accrued expenses and other current liabilities
Changes in deferred revenue
Net cash used in operating activities

Investing activities:
Purchase of property, plant and equipment, including internal use software
Purchase of available-for-sale debt securities
Maturities of marketable securities
Purchases of marketable securities
Net cash used in investing activities
Financing activities:
Transaction costs on issue of shares
Transaction costs on issue of equity securities
Proceeds from payment of shareholder loan
Proceeds from offering of Ordinary shares and Pre-Funded Warrants
February 2024 Offering
December 2024 Offering
Transaction costs on issue of Ordinary Shares and Pre-Funded Warrants
February 2024 Offering
December 2024 Offering
Proceeds from exercise of warrants
Proceeds from exercise of options
Payment of withholding taxes related to net share settlement of exercised options
Net cash provided by financing activities

Net change in cash, cash equivalents and restricted cash
Foreign exchange differences
Cash, cash equivalents and restricted cash at the beginning of the year
Cash, cash equivalents and restricted cash at the end of the year
Noncash financing and investing activities
Derivative earnout obligation recognized related to the Business Combination (as defined in Note 3)
Liabilities assumed in the Business Combination (as defined in Note 3)
Contribution of interest in NewAmsterdam Pharma Holding B.V. by Participating Shareholders (as defined in Note 3)
Issuance of Ordinary Shares to Participating Shareholders (as defined in Note 3)
Issuance of Ordinary Shares pursuant to the Profit Right Agreement (as defined in Note 2)
Recognition of ROU asset
Issuance of earnout shares

Supplemental cash flow disclosures
Cash paid for interest
Cash paid for income taxes

Reconciliation of cash, cash equivalents and restricted cash to the Consolidated Balance Sheets
Cash and cash equivalents
Restricted cash

Comments